CLASS II Drug recall · Reported 22 Jan 2020 · FDA Enforcement Report

Ketorolac Tromethamine Injection, USP 60 mg/ (30 mg/mL) recalled

Hikma Pharmaceuticals USA is recalling Ketorolac Tromethamine Injection, USP 60 mg/ (30 mg/mL), distributed nationwide in the US. The recall was initiated on 17 Dec 2019 and the FDA has classified it as Class II.

Check your package

Lot, batch or date codes038368, Exp. Mar 2020; 058314, Exp. May 2020; 078305, 078307, Exp. July 2020; 118362 Exp. Nov 2020
NDC0641-6041, 0641-6043, 0641-6042
Quantity recalled25,817 shelf packs/25 vials per pack

Check the lot number on your package against the affected lots. If it matches, contact the pharmacy that dispensed it or your prescriber before stopping any medication.

Recall details

Recall number
D-0658-2020
FDA event ID
84534
Recalling firm
Hikma Pharmaceuticals USA, Cherry Hill, NJ
Manufacturer
Hikma Pharmaceuticals USA Inc.
Classification
Class II
Status
Terminated
Recall initiated
17 Dec 2019
FDA classified
2 Mar 2020
Reported
22 Jan 2020
Type
Voluntary: Firm initiated
Customers notified by
Letter
Reason category
Particulate Matter
Drug class
Pain Medication

Timeline

17 Dec 2019Recall initiated by company
22 Jan 2020Published in enforcement report+36 days
2 Mar 2020Classified by FDA+40 days

Companies usually start a recall weeks before the FDA classifies and publishes it; the gap above is that lag.

Reason for recall

Presence of Particulate Matter: particles identified as polydimethylsiloxane (PDMS)

Product as listed by the FDA

Ketorolac Tromethamine Injection, USP 60 mg/2 mL (30 mg/mL), packaged in 2 mL Single Dose Vials (NDC 0641-6043-01), 25 vials/shelf-pack (NDC 0641-6043-25), For IM Use Only, Rx only, Manufactured by: WEST-WARD Eatontown, NJ 07724 USA.

Where it was distributed

Nationwide within the United States

Nationwide

Questions about this recall

Why was it recalled?

Presence of Particulate Matter: particles identified as polydimethylsiloxane (PDMS)

Which lots are affected?

038368, Exp. Mar 2020; 058314, Exp. May 2020; 078305, 078307, Exp. July 2020; 118362 Exp. Nov 2020

Where was it sold?

Nationwide within the United States

What should I do if I have it?

Check the lot number on your package against the affected lots. If it matches, contact the pharmacy that dispensed it or your prescriber before stopping any medication.

What does Class II mean?

Class II means the product may cause temporary or medically reversible health problems, or the probability of serious harm is remote.

Read the official FDA notice · Source record retrieved 26 Sep 2026. The FDA describes openFDA data as unvalidated; the official notice takes precedence. This page reports the record and gives no medical advice.

Other products in this recall event

1 other product · FDA event 84534
ReportedClassRecallCompanyReasonWhere
CLASS IKetorolac Tromethamine Injection, USP 30 mg/mL recalledKetorolac TromethamineHikma Pharmaceuticals USAParticulate MatterNationwide

More recalls from Hikma Pharmaceuticals USA

All 20

Other Ketorolac Tromethamine recalls

All 24